- Home
- MYGN vs DLY Comparison
MYGN vs DLY Comparison
Compare MYGN & DLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- DLY
- Stock Information
- Founded
- MYGN 1991
- DLY 2019
- Country
- MYGN United States
- DLY United States
- Employees
- MYGN N/A
- DLY N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DLY Investment Managers
- Sector
- MYGN Health Care
- DLY Finance
- Exchange
- MYGN Nasdaq
- DLY Nasdaq
- Market Cap
- MYGN 744.7M
- DLY 703.9M
- IPO Year
- MYGN 1995
- DLY N/A
- Fundamental
- Price
- MYGN $4.92
- DLY $15.49
- Analyst Decision
- MYGN Hold
- DLY
- Analyst Count
- MYGN 15
- DLY 0
- Target Price
- MYGN $15.14
- DLY N/A
- AVG Volume (30 Days)
- MYGN 2.1M
- DLY 215.9K
- Earning Date
- MYGN 08-05-2025
- DLY 01-01-0001
- Dividend Yield
- MYGN N/A
- DLY 8.93%
- EPS Growth
- MYGN N/A
- DLY N/A
- EPS
- MYGN N/A
- DLY N/A
- Revenue
- MYGN $831,300,000.00
- DLY N/A
- Revenue This Year
- MYGN N/A
- DLY N/A
- Revenue Next Year
- MYGN $6.68
- DLY N/A
- P/E Ratio
- MYGN N/A
- DLY N/A
- Revenue Growth
- MYGN 7.38
- DLY N/A
- 52 Week Low
- MYGN $3.81
- DLY $13.26
- 52 Week High
- MYGN $29.30
- DLY $15.95
- Technical
- Relative Strength Index (RSI)
- MYGN 46.03
- DLY 45.98
- Support Level
- MYGN $4.78
- DLY $15.58
- Resistance Level
- MYGN $5.29
- DLY $15.75
- Average True Range (ATR)
- MYGN 0.32
- DLY 0.11
- MACD
- MYGN 0.11
- DLY -0.03
- Stochastic Oscillator
- MYGN 60.98
- DLY 13.09
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.